Abbott Laboratories Corporation

Sean M Mellican

Geoff G Z Zhang

Rodger F Henry

Geoff G Zhang

Gregory S Wayne

David R Willcox

Jeffrey M Breting

Jianzhang Mei

Jason S Tedrow

Cathie L Linton

Nahathai Charukamnoetkanok

Greg S Wayne

The present invention relates to the salt (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate and to methods of preparing the salt.

(1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate

A crystalline N-(4-(4-aminothieno[2,3 -d]pyrimidin-5-yl)phenyl)-N'-(2-fluoro-5-(trifluoromethyl)phenyl)urea ethanolate characterized in the monoclinic crystal system and P2/n space group, when measured with radiation at 0.7107 &#x212b;, by lattice parameters a, b and c of 5.0318 &#x212b;&#xb1;0.006 &#x212b;, 23.684 &#x212b;&#xb1;0.002 &#x212b; and 18.877 &#x212b;&#xb1;0.002 &#x212b;, respectively, and &#x3b2; of 90.703&#xb1;0.003, ways to make it, compositions comprising it, and methods of treatment using it are disclosed.

Crystalline N-(4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl)-N'-(2-fluoro-5-(trifluoromethyl)phenyl)urea ethanolate

A crystalline N-(4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl)-N'-(2-fluoro-5-(trifluoromethyl)phenyl)urea benzenesulfonate characterized in the triclinic crystal system and P-1 space group, when measured with radiation at 0.7107 &#x212b;, by lattice parameters a, b and c of 7.800 &#x212b;&#xb1;0.001 &#x212b;, 13.406 &#x212b;&#xb1;0.002 &#x212b; and 13.554 &#x212b;&#xb1;0.002 &#x212b;, respectively and &#x3b1;, &#x3b2; and &#x3b3; of 67.155&#xb1;0.002, 79.724&#xb0;&#xb1;0.002&#xb0; and 84.067&#xb1;0.002, respectively, ways to make it, compositions comprising it, and methods of treatment using it are disclosed.

Crystalline N-(4-(4-ammoniumthieno[2,3-d]pyrimidin-5-yl)phenyl)-N'-(2-fluoro-5-(trifluoromethyl)phenyl)urea benzenesulfonate

Growing community of inventors

Gurnee, IL, United States of America

Sean M Mellican